サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ドライアイ症候群治療- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年：適応症別、製品タイプ別、剤形別、タイプ別、流通チャネル別、地域別、競合
市場調査レポート
商品コード
1255239

ドライアイ症候群治療- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年：適応症別、製品タイプ別、剤形別、タイプ別、流通チャネル別、地域別、競合

Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication, By Product Type, By Dosage Form, By Type, By Distribution Channel, By Region, and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ドライアイ症候群治療- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年：適応症別、製品タイプ別、剤形別、タイプ別、流通チャネル別、地域別、競合
出版日: 2023年04月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

ドライアイ症候群治療の世界市場は、予測期間中に目覚ましい成長を遂げると予測されています。

これは、関節リウマチ、甲状腺疾患、ループスなど、特定の疾患によるドライアイ症候群の有病率が世界的に高まっていることに起因しています。また、新しい点眼薬の承認や発売の増加、ドライアイ疾患の新しい治療法開発のためのヘルスケア分野における研究開発活動の活発化も、予測期間中のドライアイ症候群治療市場をさらにサポートすると予想されます。米国では、12万人以上が緑内障で失明しており、失明症例の9%から12%を占めています。また、成人の涙の分泌量を増加させる鼻腔内涙液神経刺激装置の開拓が進んでおり、新しい治療法の開発とともに、予測期間中の市場成長を後押しするものと思われます。また、市場における新規参入企業の増加により、規制当局の承認が進み、市場の成長がさらに促進されると予想されます。

ドライアイ疾患の有病率の増加

最も一般的なドライアイ疾患は慢性的な眼科疾患であり、成人と比較して高齢者層で高い有病率を示しています。スクリーンの使用頻度の増加、不適切な食事の摂取、コンタクトレンズの使用頻度の増加、世界のレーシック手術件数の増加が、予測期間中の市場成長をさらに促進します。年齢が上がるにつれて、涙腺の涙を作る能力が低下し、ドライアイ状態になることが、ドライアイ症候群の需要に貢献し、予測期間中の市場成長を促進する重要な要因の1つとなっています。National Health and Wellness Surveyのデータによると、米国の成人人口の6.8%（約1,640万人）がDEDと診断されています。

ヘルスケア産業への投資の拡大

さらに、ドライアイ症候群の新しい治療法に関する認識を広めるための公的機関や民間団体のイニシアティブの高まりは、ドライアイ症候群治療市場を長年にわたり推進することになるでしょう。食生活の変化と座りがちなライフスタイルは、予測期間中の市場ダイナミクスに影響を与える要因です。世界中で眼科医療センターが開拓され、発展途上地域全体でOTC点眼薬市場の浸透が進んでいることは、予測期間中の市場成長をさらに後押しするでしょう。2022年1月、サンファーマはカナダでCequaという名前のドライアイ治療製品を発売すると発表しました。これは、ナノミセル（NCELL）技術で送達される最初のドライアイ疾患治療薬です。この技術は、シクロスポリンのバイオアベイラビリティだけでなく、物理化学的安定性を高め、眼組織への浸透を高めるものです。

最近の開発状況

  • 2019年10月、Sun Pharmaceutical Industries Ltdは、米国でドライアイ症候群治療「CEQUA」と、米国FDAが承認した最高濃度の眼科用シクロスポリンを発売しました。
  • 2019年7月、Novartisは、ドライアイ別炎症を制御することでドライアイの徴候と症状の両方を治療することが承認された最初で唯一の処方薬であるXiidra 5%の買収が成功裏に完了したと発表しました。

利用可能なカスタマイズ

与えられた市場データをもとに、TechSci Researchは企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です。

企業情報

  • 追加市場プレイヤー（最大5社）の詳細分析およびプロファイリング。

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 研究対象年
    • 主な市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主な協会と二次情報
  • 調査手法
  • データの三角測量と検証
  • 前提条件と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレイヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向

第4章 VOC (顧客の声)

第5章 臨床試験の解析

  • 進行中の臨床試験
  • 終了した臨床試験
  • 終了した臨床試験
  • パイプラインの内訳（開発段階別）
  • パイプラインの内訳（ステータス別）
  • パイプラインの内訳（研究タイプ別）
  • パイプラインの地域別内訳
  • クリニカル・トライアル・ヒートマップ

第6章 ドライアイ症候群治療の世界市場展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 適応症別（蒸発性ドライアイ症候群／房水欠乏性ドライアイ症候群）
    • 製品タイプ別（シクロスポリン、副腎皮質ホルモン外用剤、人工涙液、穿刺プラグ、その他）
    • 剤形別（ゲル、アイソリューション、カプセル・錠剤、点眼薬、軟膏剤）
    • 種類別（処方薬／市販薬）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2022年）
  • マーケットマップ
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 地域別

第7章 北米ドライアイ症候群治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 国別
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州ドライアイ症候群治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋ドライアイ症候群治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域の：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米ドライアイ症候群治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカドライアイ症候群治療の市場展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 表示別
    • 製品タイプ別
    • 剤形別
    • タイプ別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカのドライアイ症候群治療
    • サウジアラビアのドライアイ症候群治療
    • UAEのドライアイ症候群治療

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と開拓

  • 最近の動向
  • M&A（合併・買収
  • 製品発表会

第14章 競合情勢

  • Johnson & Johnson
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc.

第15章 戦略的な提言

目次
Product Code: 14428

The Global Dry Eye Syndrome Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of dry eye syndrome due to certain diseases, such as rheumatoid arthritis, thyroid diseases, and lupus, across the globe. Besides, increasing drug approvals and launches of new eye drops, along with rising research and development activities in the healthcare sector for the development of new treatments for dry eye diseases across the globe, are further expected to support the dry eye syndrome treatment market during the forecast period. In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also, the growing development of intranasal tear neurostimulation devices, which will increase tear production in adults, along with the development of new treatment modalities, will boost the market growth during the forecasted period. Also, the rising number of new players in the market is anticipated to lead the regulatory approvals and further propel the growth of the market.

Growing Prevalence of Dry Eye Disease

The most common dry eye disease is a chronic ophthalmic disorder which has a high prevalence rate among the aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses, and the rising number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases, which leads to a dry eye condition which is one of the key factors contributing to the demand for dry eye syndrome and driving the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.

Growing investment in Healthcare Industry

Furthermore, growing initiatives by public and private organizations to spread awareness about the new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary patterns and sedentary lifestyles are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centers across the globe and growing penetration of the OTC eyedrop market across developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of a dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nano micellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.

Market Segmentation

The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel, and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over Counter. Based on distribution channels, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global dry eye syndrome treatment market on account of the growing demand for dry eye treatment in the country.

Recent Developments

  • In October 2019, Sun Pharmaceutical Industries Ltd launched a product called CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use, which is approved by the U.S. FDA.
  • In July 2019, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.

Market Players

Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.

Report Scope

In this report, global dry eye syndrome treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

  • Evaporative Dry Eye Syndrome
  • Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Dry Eye Syndrome Treatment Market, By Type:

  • Prescription
  • Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)
    • 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
    • 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
    • 6.2.4. By Type (Prescription v/s Over The Counter)
    • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.6. By Region
    • 6.2.7. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Indication
    • 6.3.2. By Product Type
    • 6.3.3. By Dosage Form
    • 6.3.4. By Type
    • 6.3.5. By Distribution Channel
    • 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product Type
    • 7.2.3. By Dosage Form
    • 7.2.4. By Type
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Type
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Type
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Type
        • 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product Type
    • 8.2.3. By Dosage Form
    • 8.2.4. By Type
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Type
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Type
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Type
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Type
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Type
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product Type
    • 9.2.3. By Dosage Form
    • 9.2.4. By Type
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Type
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Type
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Type
        • 9.3.3.2.5. By Distribution Channel
    • 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Product Type
        • 9.3.4.2.3. By Dosage Form
        • 9.3.4.2.4. By Type
        • 9.3.4.2.5. By Distribution Channel
    • 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Product Type
        • 9.3.5.2.3. By Dosage Form
        • 9.3.5.2.4. By Type
        • 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product Type
    • 10.2.3. By Dosage Form
    • 10.2.4. By Type
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Type
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Type
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Type
        • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Product Type
    • 11.2.3. By Dosage Form
    • 11.2.4. By Type
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Dosage Form
        • 11.3.1.2.4. By Type
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Dosage Form
        • 11.3.2.2.4. By Type
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Product Type
        • 11.3.3.2.3. By Dosage Form
        • 11.3.3.2.4. By Type
        • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Johnson & Johnson
    • 14.6.2. AbbVie Inc.
    • 14.6.3. Bausch Health Companies Inc.
    • 14.6.4. Novartis AG
    • 14.6.5. Sun Pharmaceuticals Industries Limited
    • 14.6.6. Santen Pharmaceutical Co., Ltd.
    • 14.6.7. Otsuka Pharmaceutical Co., Ltd.
    • 14.6.8. Oyster Point Pharma, Inc.
    • 14.6.9. Alcon Inc.
    • 14.6.10. GlaxoSmithKline plc.

15. Strategic Recommendations